Summary
Johnson & Johnson, through its subsidiary Janssen Biotech, Inc., has entered into a significant worldwide collaboration and license agreement with Legend Biotech for the development and commercialization of a novel CAR T-cell therapy candidate, LCAR-B38M. This drug targets BCMA and is being developed for multiple myeloma. This strategic move positions Johnson & Johnson at the forefront of advanced oncology treatments, particularly in the promising field of cell therapy. The agreement includes an upfront payment of $350 million and potential future milestone payments, highlighting the perceived value and potential of LCAR-B38M. The collaboration features a 50/50 cost-sharing and profit-split arrangement globally, except for Greater China where Janssen will have a 30/70 split. This partnership signifies a substantial investment in a cutting-edge therapy and underscores JNJ's commitment to expanding its oncology pipeline.
Key Highlights
- 1Janssen Biotech enters a worldwide collaboration and license agreement with Legend Biotech for CAR T-cell drug candidate LCAR-B38M.
- 2LCAR-B38M targets BCMA for the treatment of multiple myeloma.
- 3The drug candidate is accepted for review by the China Food and Drug Administration (CFDA) and is in the planning phase for U.S. clinical studies.
- 4Janssen will make an upfront payment of $350 million, with additional payments contingent on development, regulatory, and sales milestones.
- 5A 50/50 cost-sharing and profit-split arrangement is established globally, with a 30/70 split in Greater China.
- 6Johnson & Johnson reaffirms its previously announced adjusted earnings guidance for full-year 2017 ($7.25-$7.30 per share).